Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial

Pirkko-Liisa Kellokumpu-Lehtinen; Timo Marttila; Antti Jekunen; Petteri Hervonen; Katariina Klintrup; Vesa Kataja; Tapio Utriainen; Marjaana Luukkaa; Markku Leskinen; Kalevi Pulkkanen; Anna-Liisa Kautio; Teppo Huttunen

doi:10.21873/anticanres.14715

Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial

Pirkko-Liisa Kellokumpu-Lehtinen, Timo Marttila, Antti Jekunen, Petteri Hervonen, Katariina Klintrup, Vesa Kataja, Tapio Utriainen, Marjaana Luukkaa, Markku Leskinen, Kalevi Pulkkanen, Anna-Liisa Kautio, Teppo Huttunen

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Anticancer Research
Volume	40
Issue number	12
Pages (from-to)	6915-6921
Number of pages	7
ISSN	0250-7005
DOIs	https://doi.org/10.21873/anticanres.14715
Publication status	Published - Dec 2020
MoE publication type	A1 Journal article-refereed

Fields of Science

mCRPC
cabazitaxel
postdocetaxel
biweekly dosing
MITOXANTRONE PLUS PREDNISONE
INCREASED SURVIVAL
PHASE-III
THERAPY
RECOMMENDATIONS
ENZALUTAMIDE
ABIRATERONE
MANAGEMENT
3122 Cancers

Access to Document

10.21873/anticanres.14715

6915.fullFinal published version, 156 KB

Cite this

Kellokumpu-Lehtinen, P.-L., Marttila, T., Jekunen, A., Hervonen, P., Klintrup, K., Kataja, V., Utriainen, T., Luukkaa, M., Leskinen, M., Pulkkanen, K., Kautio, A.-L., & Huttunen, T. (2020). Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial. Anticancer Research, 40(12), 6915-6921. https://doi.org/10.21873/anticanres.14715

@article{5b83ea6e7f3647bfa926d96c77c1a054,

title = "Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial",

keywords = "mCRPC, cabazitaxel, postdocetaxel, biweekly dosing, MITOXANTRONE PLUS PREDNISONE, INCREASED SURVIVAL, PHASE-III, THERAPY, RECOMMENDATIONS, ENZALUTAMIDE, ABIRATERONE, MANAGEMENT, 3122 Cancers",

author = "Pirkko-Liisa Kellokumpu-Lehtinen and Timo Marttila and Antti Jekunen and Petteri Hervonen and Katariina Klintrup and Vesa Kataja and Tapio Utriainen and Marjaana Luukkaa and Markku Leskinen and Kalevi Pulkkanen and Anna-Liisa Kautio and Teppo Huttunen",

year = "2020",

month = dec,

doi = "10.21873/anticanres.14715",

language = "English",

volume = "40",

pages = "6915--6921",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

Kellokumpu-Lehtinen, P-L, Marttila, T, Jekunen, A, Hervonen, P, Klintrup, K, Kataja, V, Utriainen, T, Luukkaa, M, Leskinen, M, Pulkkanen, K, Kautio, A-L & Huttunen, T 2020, 'Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial', Anticancer Research, vol. 40, no. 12, pp. 6915-6921. https://doi.org/10.21873/anticanres.14715

Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial. / Kellokumpu-Lehtinen, Pirkko-Liisa; Marttila, Timo; Jekunen, Antti et al.
In: Anticancer Research, Vol. 40, No. 12, 12.2020, p. 6915-6921.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Marttila, Timo

AU - Jekunen, Antti

AU - Hervonen, Petteri

AU - Klintrup, Katariina

AU - Kataja, Vesa

AU - Utriainen, Tapio

AU - Luukkaa, Marjaana

AU - Leskinen, Markku

AU - Pulkkanen, Kalevi

AU - Kautio, Anna-Liisa

AU - Huttunen, Teppo

PY - 2020/12

Y1 - 2020/12

KW - mCRPC

KW - cabazitaxel

KW - postdocetaxel

KW - biweekly dosing

KW - MITOXANTRONE PLUS PREDNISONE

KW - INCREASED SURVIVAL

KW - PHASE-III

KW - THERAPY

KW - RECOMMENDATIONS

KW - ENZALUTAMIDE

KW - ABIRATERONE

KW - MANAGEMENT

KW - 3122 Cancers

U2 - 10.21873/anticanres.14715

DO - 10.21873/anticanres.14715

M3 - Article

SN - 0250-7005

VL - 40

SP - 6915

EP - 6921

JO - Anticancer Research

JF - Anticancer Research

IS - 12

ER -